BRPI0910175A2 - composto de fórmula i e ii, composição farmacêutica, método de inibição do crescimento de células anormais ou de tratamento de um distúrbio hiperproliferativo em um mamífero e método de tratamento de uma doença inflamatória em um mamífero - Google Patents
composto de fórmula i e ii, composição farmacêutica, método de inibição do crescimento de células anormais ou de tratamento de um distúrbio hiperproliferativo em um mamífero e método de tratamento de uma doença inflamatória em um mamíferoInfo
- Publication number
- BRPI0910175A2 BRPI0910175A2 BRPI0910175A BRPI0910175A BRPI0910175A2 BR PI0910175 A2 BRPI0910175 A2 BR PI0910175A2 BR PI0910175 A BRPI0910175 A BR PI0910175A BR PI0910175 A BRPI0910175 A BR PI0910175A BR PI0910175 A2 BRPI0910175 A2 BR PI0910175A2
- Authority
- BR
- Brazil
- Prior art keywords
- mammal
- treating
- compound
- formula
- pharmaceutical composition
- Prior art date
Links
- 241000124008 Mammalia Species 0.000 title 2
- 230000002159 abnormal effect Effects 0.000 title 1
- 230000010261 cell growth Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000003463 hyperproliferative effect Effects 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7742608P | 2008-07-01 | 2008-07-01 | |
| PCT/US2009/049453 WO2010003025A1 (en) | 2008-07-01 | 2009-07-01 | Bicyclic heterocycles as mek kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0910175A2 true BRPI0910175A2 (pt) | 2017-03-21 |
Family
ID=41038842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0910175A BRPI0910175A2 (pt) | 2008-07-01 | 2009-07-01 | composto de fórmula i e ii, composição farmacêutica, método de inibição do crescimento de células anormais ou de tratamento de um distúrbio hiperproliferativo em um mamífero e método de tratamento de uma doença inflamatória em um mamífero |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8841462B2 (https=) |
| EP (1) | EP2310373A1 (https=) |
| JP (1) | JP5544358B2 (https=) |
| KR (1) | KR20110029161A (https=) |
| CN (1) | CN102137847B (https=) |
| AU (1) | AU2009266956B2 (https=) |
| BR (1) | BRPI0910175A2 (https=) |
| CA (1) | CA2727250A1 (https=) |
| CL (1) | CL2010001641A1 (https=) |
| IL (1) | IL209931A0 (https=) |
| MX (1) | MX2010014559A (https=) |
| PE (1) | PE20110570A1 (https=) |
| RU (1) | RU2509078C2 (https=) |
| WO (1) | WO2010003025A1 (https=) |
| ZA (1) | ZA201008963B (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010317167B2 (en) | 2009-11-04 | 2012-11-29 | Novartis Ag | Heterocyclic sulfonamide derivatives useful as MEK inhibitors |
| CN102020651B (zh) | 2010-11-02 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 6-芳基氨基吡啶酮甲酰胺mek抑制剂 |
| EA201391820A1 (ru) * | 2011-06-09 | 2014-12-30 | Новартис Аг | Гетероциклические сульфонамидные производные |
| US20150265679A1 (en) | 2012-11-02 | 2015-09-24 | The United States Of America, As Represented By Secretary, Department Of Health And Human Services | Method of reducing adverse effects in a cancer patient undregoing treatment with a mek inhibitor |
| US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| NO2714752T3 (https=) | 2014-05-08 | 2018-04-21 | ||
| US20170114323A1 (en) | 2014-06-19 | 2017-04-27 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| CN104119332B (zh) * | 2014-07-08 | 2019-03-29 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的苯并杂环化合物及其制备方法和用途 |
| CN104860869B (zh) * | 2015-04-03 | 2017-11-03 | 北京大学 | 具有mek激酶抑制功能的化合物及其制备方法与应用 |
| HUE050317T2 (hu) | 2015-05-20 | 2020-11-30 | Amgen Inc | APJ receptor triazol agonistái |
| WO2017033113A1 (en) | 2015-08-21 | 2017-03-02 | Acerta Pharma B.V. | Therapeutic combinations of a mek inhibitor and a btk inhibitor |
| GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| KR20180134347A (ko) | 2016-04-15 | 2018-12-18 | 제넨테크, 인크. | 암의 진단 및 치료 방법 |
| US9988369B2 (en) | 2016-05-03 | 2018-06-05 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the APJ receptor |
| ES2896943T3 (es) | 2016-10-28 | 2022-02-28 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Compuesto de amino pirazolopirimidina usado como inhibidor de receptores con actividad tirosina quinasa de factores neurotróficos |
| US10736883B2 (en) | 2016-11-16 | 2020-08-11 | Amgen Inc. | Triazole furan compounds as agonists of the APJ receptor |
| EP3541803B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
| WO2018093579A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole phenyl compounds as agonists of the apj receptor |
| US11046680B1 (en) | 2016-11-16 | 2021-06-29 | Amgen Inc. | Heteroaryl-substituted triazoles as APJ receptor agonists |
| WO2018093576A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the apj receptor |
| WO2018093577A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the apj receptor |
| KR102811888B1 (ko) | 2017-09-08 | 2025-05-27 | 에프. 호프만-라 로슈 아게 | 암의 진단 및 치료 방법 |
| MA50509A (fr) | 2017-11-03 | 2021-06-02 | Amgen Inc | Agonistes de triazole fusionnés du récepteur apj |
| EP3752200A1 (en) | 2018-02-13 | 2020-12-23 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| US11807624B2 (en) | 2018-05-01 | 2023-11-07 | Amgen Inc. | Substituted pyrimidinones as agonists of the APJ receptor |
| JP2023504623A (ja) * | 2019-12-04 | 2023-02-06 | アーカス バイオサイエンシーズ，インコーポレーテッド | Ｈｉｆ－２アルファの阻害剤 |
| CA3197685A1 (en) | 2020-10-29 | 2022-05-05 | Shenzhen Chipscreen Biosciences Co., Ltd. | Biphenyl compound as immunomodulator, preparation method therefor and application thereof |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| US12280055B2 (en) | 2021-05-27 | 2025-04-22 | Mirati Therapeutics, Inc. | Combination therapies |
| CN113336786B (zh) * | 2021-05-31 | 2022-10-18 | 南京工业大学 | 一种非对映选择性的多取代环烷基化合物及其制备方法 |
| US20260048075A1 (en) | 2022-08-10 | 2026-02-19 | Vib Vzw | Inhibition of TCF4/ITF2 in the Treatment of Cancer |
| WO2026019990A1 (en) | 2024-07-18 | 2026-01-22 | Genentech, Inc. | Methods of treating cancer with anti-ccr8/anti-cd3 bispecific antibodies |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2017853C3 (de) | 1970-04-14 | 1975-12-11 | Standard Elektrik Lorenz Ag, 7000 Stuttgart | Steuerverfahren zur Sicherung der Informationsverarbeitung und -Übertragung |
| CA920592A (en) * | 1970-05-28 | 1973-02-06 | Denzel Theodor | Amino derivatives of pyrazolo-pyridine carboxylic acids and esters |
| US3736326A (en) * | 1971-03-29 | 1973-05-29 | Squibb & Sons Inc | Isoxazolopyridine carboxylic acids and esters |
| US3780047A (en) * | 1972-07-05 | 1973-12-18 | Squibb & Sons Inc | Derivatives of pyrazolo(3',4'-2,3)pyrido(4,5-e)b-benzo-1,5-diazepines |
| US4012373A (en) * | 1972-09-22 | 1977-03-15 | E. R. Squibb & Sons, Inc. | Pyrazolo[3',4'-2,3]pyrido[4,5-e]b-benzo-1,5-diazepinones |
| GB8404586D0 (en) * | 1984-02-22 | 1984-03-28 | Beecham Group Plc | Compounds |
| JP2002020386A (ja) * | 2000-07-07 | 2002-01-23 | Ono Pharmaceut Co Ltd | ピラゾロピリジン誘導体 |
| JP3811775B2 (ja) | 2000-07-19 | 2006-08-23 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | ４−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル |
| US20050009876A1 (en) * | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
| KR100984595B1 (ko) | 2002-03-13 | 2010-09-30 | 어레이 바이오파마 인크. | Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체 |
| EP1482944A4 (en) | 2002-03-13 | 2006-04-19 | Array Biopharma Inc | NZ ALKYL BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS |
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| CL2003002287A1 (es) * | 2002-11-25 | 2005-01-14 | Wyeth Corp | COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS |
| GB0316237D0 (en) | 2003-07-11 | 2003-08-13 | Astrazeneca Ab | Therapeutic agents |
| GB0316232D0 (en) | 2003-07-11 | 2003-08-13 | Astrazeneca Ab | Therapeutic agents |
| US20050049276A1 (en) | 2003-07-23 | 2005-03-03 | Warner-Lambert Company, Llc | Imidazopyridines and triazolopyridines |
| ATE506953T1 (de) | 2003-08-07 | 2011-05-15 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel |
| US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
| US7144907B2 (en) * | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| CN1905873A (zh) | 2003-11-19 | 2007-01-31 | 阵列生物制药公司 | Mek的杂环抑制剂及其使用方法 |
| ATE386715T1 (de) | 2003-11-25 | 2008-03-15 | Lilly Co Eli | Modulatoren des peroxisomproliferatoraktivierten rezeptors |
| AU2004299438A1 (en) | 2003-12-19 | 2005-06-30 | Biovitrum Ab | Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-HT6 receptor-related disorder |
| JP4805166B2 (ja) | 2003-12-22 | 2011-11-02 | バジリア ファルマスーチカ アーゲー | アロイルフランおよびアロイルチオフェン |
| WO2005063296A2 (en) | 2003-12-23 | 2005-07-14 | Pfizer Products Inc. | Therapeutic combination for cognition enhancement and psychotic disorders |
| WO2007027855A2 (en) | 2005-09-01 | 2007-03-08 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| SI1934174T1 (sl) * | 2005-10-07 | 2011-08-31 | Exelixis Inc | Inhibitorji MEK in postopki za njihovo uporabo |
| WO2008028141A2 (en) | 2006-08-31 | 2008-03-06 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
-
2009
- 2009-07-01 US US12/999,003 patent/US8841462B2/en not_active Expired - Fee Related
- 2009-07-01 JP JP2011516860A patent/JP5544358B2/ja not_active Expired - Fee Related
- 2009-07-01 MX MX2010014559A patent/MX2010014559A/es active IP Right Grant
- 2009-07-01 CN CN200980133788.0A patent/CN102137847B/zh not_active Expired - Fee Related
- 2009-07-01 WO PCT/US2009/049453 patent/WO2010003025A1/en not_active Ceased
- 2009-07-01 PE PE2010001198A patent/PE20110570A1/es not_active Application Discontinuation
- 2009-07-01 KR KR1020117002481A patent/KR20110029161A/ko not_active Ceased
- 2009-07-01 RU RU2011103454/04A patent/RU2509078C2/ru not_active IP Right Cessation
- 2009-07-01 BR BRPI0910175A patent/BRPI0910175A2/pt not_active IP Right Cessation
- 2009-07-01 AU AU2009266956A patent/AU2009266956B2/en not_active Ceased
- 2009-07-01 EP EP09774475A patent/EP2310373A1/en not_active Withdrawn
- 2009-07-01 CA CA2727250A patent/CA2727250A1/en not_active Abandoned
-
2010
- 2010-12-12 IL IL209931A patent/IL209931A0/en unknown
- 2010-12-13 ZA ZA2010/08963A patent/ZA201008963B/en unknown
- 2010-12-30 CL CL2010001641A patent/CL2010001641A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP5544358B2 (ja) | 2014-07-09 |
| MX2010014559A (es) | 2011-03-04 |
| AU2009266956A1 (en) | 2010-01-07 |
| RU2011103454A (ru) | 2012-08-10 |
| CL2010001641A1 (es) | 2011-07-15 |
| KR20110029161A (ko) | 2011-03-22 |
| AU2009266956B2 (en) | 2014-03-20 |
| US20110190257A1 (en) | 2011-08-04 |
| JP2011526926A (ja) | 2011-10-20 |
| AU2009266956A2 (en) | 2011-03-10 |
| CA2727250A1 (en) | 2010-01-07 |
| EP2310373A1 (en) | 2011-04-20 |
| CN102137847A (zh) | 2011-07-27 |
| ZA201008963B (en) | 2012-03-28 |
| US8841462B2 (en) | 2014-09-23 |
| CN102137847B (zh) | 2015-06-10 |
| IL209931A0 (en) | 2011-02-28 |
| WO2010003025A1 (en) | 2010-01-07 |
| PE20110570A1 (es) | 2011-08-26 |
| RU2509078C2 (ru) | 2014-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0910175A2 (pt) | composto de fórmula i e ii, composição farmacêutica, método de inibição do crescimento de células anormais ou de tratamento de um distúrbio hiperproliferativo em um mamífero e método de tratamento de uma doença inflamatória em um mamífero | |
| BRPI0910200A2 (pt) | composto, composição farmacêutica, método de inibir o crescimento de células anormais ou de tratar um distúrbio hiperproliferativo em um mamífero e método de tratar uma doença inflamatória em um mamífero | |
| BRPI0819529A2 (pt) | "composto de fórmula i, composição farmacêutica, método para inibir o crescimento celular anormal ou tratar um distúrbio hiperproliferativo em um mamífero e método para tratar uma doença inflamatória em um mamífero" | |
| BRPI0909957A2 (pt) | "composto, composição farmacêutica, método de inibir o crescimento anormal de células ou de tratar um distúrbio hiperproliferativo em um mamífero, método de tratamento do câncer em um mamífero" | |
| BRPI0921317A2 (pt) | composto, composição farmacêutica, e, método para tratar ou prevenir uma patologia relacionada com abeta em um mamífero | |
| BRPI0915267A2 (pt) | Composto, composição farmacêutica livre de pirogênio, e, método de tratamento de uma doença ou uma condição | |
| BRPI0923384A2 (pt) | composto, composição farmacêutica, e, métodos para tratar um mamífero, e para inibir quimiotaxia celular | |
| BRPI0819505A2 (pt) | "composto, composição farmacêutica, método para inibir o crescimento celular anormal e método para tratar uma doença inflamatória" | |
| EP2376659A4 (en) | METHOD, COMPOSITIONS AND KITS FOR DETECTING ALL VARIANTS | |
| BRPI0909614A2 (pt) | "composto, composição farmacêutica, método de tratamento de um transtorno hiperproliferativo em um mamífero, processo para a preparação de uma composição farmacêutica, método para a inibição ou modulação da atividade de quinase de lipídio em um mamífero, kit para o tratamento de condição mediada por pi3k e método de preparação de um composto da fórmula | |
| EP2485749A4 (en) | METHOD FOR THE PREVENTION AND TREATMENT OF HEART FAILURE | |
| PL2610255T3 (pl) | Związki 1H-benzo[d]imidazol-5-ilowe i kompozycja do leczenia chorób zapalnych | |
| BRPI1008383A2 (pt) | composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto | |
| EP2429600A4 (en) | COMPOSITION FOR PREPARING A FRAMEWORK FOR TISSUE-BREEDING AND MANUFACTURING METHOD THEREFOR | |
| BRPI0914233A2 (pt) | composto, uso de um composto, métodos para produzir um efeito inibidor de fgfr e para produzir um efeito anticâncer em um animal de sangue quente, composição farmacêutica, e, método para tratar uma doença | |
| BR112012028530A2 (pt) | composto, composição farmacêutica e seu processo de preparação e método para o tratamento de uma doença ou transtorno | |
| EP2470191A4 (en) | METHOD AND COMPOSITIONS FOR PREVENTING OR TREATING EYE DISEASES | |
| IL247136B (en) | Compounds for reducing uric acid and uses thereof | |
| BR112012001761A2 (pt) | composto de formula i, composto farmacêutica e método de tratamento de uma condição mediada por metal em um indivduo | |
| BRPI0908635A2 (pt) | composto, composição farmacêutica e método de tratamento de câncer | |
| ZA201008201B (en) | Novel compositions and methods for treating hyperproliferative diseases | |
| PL2349231T3 (pl) | Kompozycje i metody leczenia chorób kopyta | |
| FI20070935L (fi) | Koostumus ja menetelmä puun käsittelemiseksi | |
| EP2549877A4 (en) | COMPOSITION AND METHOD FOR AVOIDING MALE DISEASES | |
| BRPI0911580A2 (pt) | composições para o tratamento de uma condição artrítica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |